PharmiWeb.com - Global Pharma News & Resources
09-Sep-2021

Gerresheimer AG: Continuity on the Management Board: Gerresheimer extends contract with CFO Dr. Bernd Metzner ahead of schedule by a further five years

DGAP-News: Gerresheimer AG / Key word(s): Personnel/Contract
09.09.2021 / 09:00
The issuer is solely responsible for the content of this announcement.

Continuity on the Management Board: Gerresheimer extends contract with CFO
Dr. Bernd Metzner ahead of schedule by a further five years

Duesseldorf, September 9, 2021 - At its most recent meeting, the Supervisory Board of Gerresheimer AG prematurely extended the contract of Chief Financial Officer Dr. Bernd Metzner (50) by a further five years until May 2027. The move is a strong sign of continuity and reliability on the Management Board of Gerresheimer AG. Together, the three Management Board members Dietmar Siemssen, Dr. Bernd Metzner and Dr. Lukas Burkhardt will continue to drive forward the formula G strategy, which calls for Gerresheimer's transformation into a growth company as an innovation leader and solution provider.

Dr. Bernd Metzner has already been Chief Financial Officer of Gerresheimer AG since May 2019. His contract runs until May 2027, meaning that all three Management Board members have now extended their contracts by five years.

"We have initiated a transformation together in recent years, marking the start of an exciting journey toward sustainable, profitable growth. I look forward to continuing to successfully shape the future of our Gerresheimer together with my Management Board colleagues and the entire Gerresheimer team. At the same time, I would like to thank our Supervisory Board for its trust," says Dr. Bernd Metzner.

"It is clear to us that Dr. Bernd Metzner is the ideal CFO for our company. With his long-standing expertise, he will continue to make a significant contribution to achieving our ambitious growth targets sustainably," says Dietmar Siemssen, CEO of Gerresheimer AG. "We are all looking forward to continuing to work together."

Press contact
Jens Kürten
Group Senior Director Communication & Marketing
T +49 211 6181-250
jens.kuerten@gerresheimer.com

Investor Relations contact
Carolin Nadilo
Corporate Director Investor Relations
T +49 211 6181-220
carolin.nadilo@gerresheimer.com

About Gerresheimer
Gerresheimer is the global partner for pharma, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging and drug delivery devices. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence, focus on quality and customers. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generates annual sales of more than €1.4 billion. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.



09.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Gerresheimer AG
Klaus-Bungert-Str. 4
40468 Düsseldorf
Germany
Phone: +49-(0)211/61 81-314
Fax: +49-(0)211/61 81-121
E-mail: carolin.nadilo@gerresheimer.com
Internet: http://www.gerresheimer.com
ISIN: DE000A0LD6E6
WKN: A0LD6E
Indices: MDAX (Aktie)
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1232242

 
End of News DGAP News Service

Editor Details

Last Updated: 09-Sep-2021